Yijun Xie

Yijun Xie

Auto-generated profile, based on publicly available information

Yijun Xie

Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2017 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
YXYijun Xie
Yijun Xie
YJYijie Jia
Yijie Jia
XCXie Cuihua
Xie Cuihua
FHFang Hu
Fang Hu
MXMeng Xue
Meng Xue
YXYaoming Xue
Yaoming Xue
Background. Albuminuria is an early sign but not a strong predictor of diabetic kidney disease (DKD). Owing to their high stability, urinary exosomal miRNAs can be useful predictors of the progression of early-stage DKD to renal failure; fluid biopsies are ideal for detecting abnormalities in these miRNAs. The aim of this study was to identify novel differentially expressed miRNAs as urine biomarkers for type 2 DKD by comparing between patients of type 2 diabetes (T2D) with and without macroalbuminuria. Methods. Ten patients with T2D, including five who had no renal disease and five with macroalbuminuria (DKD G1-2A3), were selected for this study. Exosome- (UExo-) derived miRNA profiles were used to identify candidate biomarkers, a subset of which was verified using quantitative reverse transcription PCR. Results. A total of 496 UExo-derived miRNA species were found to be differentially expressed (>2-fold) in patients with DKD, compared to those with T2D. A validation analysis revealed that three miRNAs (miR-362-3p, miR-877-3p, and miR-150-5p) were upregulated and one (miR-15a-5p) was downregulated. These miRNAs might regulate DKD through p53, mTOR, and AMPK pathways. Conclusions. In conclusion, UExo-derived miRNAs were altered in type 2 DKD. MiR-362-3p, miR-877-3p, miR-150-5p, and miR-15a-5p might be novel biomarkers for incipient DKD.

27 February 2018 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
YXYijun Xie
Yijun Xie
YJYijie Jia
Yijie Jia
CXCuihua Xie
Cuihua Xie
FHFang Hu
Fang Hu
MXMeng Xue
Meng Xue
YXYaoming Xue
Yaoming Xue
[This corrects the article DOI: 10.1155/2017/6978984.].

15 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
YXYijun Xie
Yijun Xie
ZJZiyu Jiang
Ziyu Jiang
ZHZhiheng Huang
Zhiheng Huang
ZCZilong Chen
Zilong Chen
HLHui Lyu
Hui Lyu
LHLing He
Ling He
Background: Triple-Negative Breast Cancer (TNBC), which lacks estrogen receptor, progesterone receptor and HER2 expression, has limited effective therapeutic options and unfavorable prognosis. Nicotinamide (NAM), a form of vitamin B3, has shown anti-tumor effects in TNBC, but the underlying regulatory mechanisms remains unclear. Methods: Transcriptomic and proteomic data from TNBC cell lines (BT20, MDA-MB-231, and MDA-MB-468) were analyzed using the ARACNe and VIPER/metaVIPER algorithms to infer regulatory activity and construct gene networks. Differentially expressed genes (DEGs) and proteins (DEPs) were integrated with regulator activity to identify key molecular drivers. Clinical outcomes were assessed using bc-GenExMiner and Kaplan– Meier Plotter, correlation and enrichment analyses were employed ICGC datasets and KEGG pathway mapping. Results: NAM treatment induced distinct but overlapping regulatory activity profiles among TNBC cell lines, with PHGDH, TSPAN1, TACSTD2, and OSBPL6 emerging as shared regulators. Among these, PHGDH, a key enzyme in the serine biosynthesis pathway, showed consistent downregulation across datasets and was associated with poor overall survival ( p < 0.001). Correlation analysis across three ICGC cohorts identified 384 genes significantly associated with PHGDH, enriched in Glycine, serine and threonine metabolicpathways. Network analysis revealed potential interactions between PHGDH, ERBB3 and other regulatory proteins, suggesting crosstalk between metabolic and signaling pathways. Conclusions: This multi-omics integration highlights PHGDH as a central metabolic regulator linking transcriptional and translational responses to NAM treatment in TNBC. These findings support PHGDH as a potential biomarker and therapeutic target, emphasizing the role of metabolic regulation in TNBC progression and treatment response.